Medicare will cover nationally Chimeric Antigen Receptor T-cell therapies approved by the Food and Drug Administration to treat certain cancers, as well as off-label uses recommended by compendia approved by the Centers for Medicare & Medicaid Services, the agency announced yesterday. The therapies, which use a patient’s own genetically modified immune cells to fight cancer, must be administered at health care facilities enrolled in FDA’s risk evaluation and mitigation strategies. Currently, the FDA has approved CAR T-cell therapy for certain types of leukemia and non-Hodgkin lymphoma. The policy also continues coverage for routine costs in certain clinical trials that use CAR T-cell therapy.

Related News Articles

Perspective
Two weeks ago, I wrote about the
Headline
The U.S. Court of Appeals for the District of Columbia Circuit reversed the voiding of a rule that included Medicare and private insurance payments when…
Headline
The AHA today voiced support for the Improving Seniors’ Timely Access to Care Act (H.R. 3107), bipartisan legislation that would establish requirements for the…
Headline
Offering a government insurance program reimbursing at Medicare rates as a public option on the health insurance exchanges could place as many as 55% of rural…
Headline
The state of Florida and city of Philadelphia each declared public health emergencies last week to address hepatitis A outbreaks.
Headline
The Centers for Medicare & Medicaid Services will discontinue the Medicare Advantage Qualifying Payment Arrangement Incentive Demonstration due